After 7 years of continuous MS treatment, about 88% had no confirmed disability progression
TG Therapeutics presented data on BRIUMVI (ublituximab) at MSToronto2026, showing 88% of patients had no disability progression after 7 years. Phase 3 ENHANCE trial supports a single-dose initiation schedule. Phase 1 data supports quarterly subcutaneous dosing. Azer-cel Phase 1 data for PPMS will be presented October 23, 2026. Michael S. Weiss, CEO, highlighted the potential of BRIUMVI in relapsing MS.
How this was made
The 30-second read
Why it matters
The data could prompt analysts to upgrade earnings forecasts and may lead to increased institutional buying.
Market read
Strong long‑term trial results are likely to lift TG Therapeutics' stock and positively affect the broader MS therapeutic space.
What to watch
Regulatory approval timeline and payer coverage decisions could moderate impact.
Background
TG Therapeutics presented extensive seven-year efficacy and safety data for its BRIUMVI (ublituximab) at MSToronto2026, highlighting low relapse rates and high disability‑free outcomes.
Ticker impact
TG Therapeutics reported seven-year BRIUMVI (ublituximab) data showing 88% of patients free from disability progression, a new primary disclosure of long-term efficacy.
likely upward pressure as investors price in durable efficacy and potential market expansion.
First report of robust 7‑year outcomes; comparable or better than prior data, may trigger re‑rating and buying interest.
Market effects
strengthens outlook for CD20 monoclonal antibody therapies in multiple sclerosis.
potentially boosts US biotech sector sentiment.
may influence global MS treatment landscape and competitor pipelines.
Counterpoint
Long-term data may not translate into immediate sales if pricing or reimbursement issues arise.
Key entities
- CompanyTG Therapeutics
US‑listed biotech developing BRIUMVI for relapsing multiple sclerosis.
- ProductBRIUMVI (ublituximab)
Anti‑CD20 monoclonal antibody therapy for MS.
